The 2017/2018 edition of our catalogue for speciality reagents in the fields of translgutaminase, celiac disease and blood coagulation combines more than 200 products.

The thematic overview is given in the section "Products". Please click on the relevant category to find the desired product.

You can download our current product catalogue or send us an e-mail to receive your personal hardcopy.
You can download an alphanumeric product List.

We constantly strive to enlarge our product portfolio. Here you can find an overview of new products we offer since the latest catalogue’s print release:

Transglutaminases


Art. No.
Name
Quantity
Price
T197 Coagulation factor XIII
(human FXIII-A2, recombinantly produced in insect cells)
100 E
250 E
685 €
1370 €
T159 Pig tissue transglutaminase
(sTG2, recombinantly produced in E. coli)
250 µg
1 mg
370 €
1100 €
T184 Cat tissue transglutaminase
(fcTG2, recombinantly produced in E. coli)
200 µg
370 €

Microbial Transglutaminase


Art. No.
Name
Quantity
Price
A144 Monoclonal antibody to microbial transglutaminase
200 µg
365 €
A143 Monoclonal antibody to microbial transglutaminase
200 µg
365 €
A145 Polyclonal antibody to bacterial transglutaminase (BTG, MTG)
200 µg
365 €

Inhibitors


Art. No.
Name
Quantity
Price
Z015 Keillor inhibitor AA9
10 mg
385 €
D016 LDN 27219
10 mg
385 €
Z016 Keillor inhibitor NC9
10 mg
385 €
Z017 Keillor inhibitor VA4
10 mg
385 €

Antibodies and Microarrays


Art. No.
Name
Quantity
Price
A139 Monoclonal antibody to human TG6 (Catalytic Domain, clone XTG52)
200 µg
365 €
A140 Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG39)
200 µg
365 €
A141 Monoclonal antibody to human TG6 (Beta Barrel 1 Domain, clone XTG68)
200 µg
365 €
A142 Monoclonal antibody to human TG6 (Beta Barrel 2 Domain, clone XTG57)
200 µg
365 €
A082 Monoclonal antibody to human TG3
200 µg
365 €

Proteases


Art. No.
Name
Quantity
Price
T222 Human Alpha Thrombin, recombinant
100 NIH Units
185 €

Celiac Disease Products


Art. No.
Name
Quantity
Price
E104 ZediXclusive TG6-ab ELISA (IgG)
Neuronal transglutaminase (TG6) ELISA IgG
1 Kit/96 wells
520 €
E103 ZediXclusive TG6-ab ELISA (IgA)
Neuronal transglutaminase (TG6) ELISA IgA
1 Kit/96 wells
520 €
G057 Alpha2-gliadin, 33mer (aa56-88), TAMRA labeled
5 mg
520 €
G058 Alpha2-gliadin, 33mer (aa56-88), TAMRA and Biotin labeled
5 mg
735 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

  • Workshop on Transglutaminase Research

    28.09.2019 - 01.10.2019
    Marrakech, Morocco